Byetta
- Two of the 155 patients treated with Byetta withdrew due to adverse reactions of headache and nausea.
Label revised Sep 2, 2025. DailyMed
From each FDA label
Do GLP-1s cause headaches?
Headaches are in the main trial table of 4 labels. The highest rate printed is 14% on Wegovy 2.4 mg (10% on placebo) and the lowest 9% on Foundayo 17.2 mg (7% on placebo). Separate trials, so not a ranking. Ozempic and Rybelsus/Ozempic tablets list it only among reports after approval, without a rate.
Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Jun 1, 2026.
Rate against placebo
How often headaches happened in each medicine's trials
At the highest dose in each label's main table. Separate trials with different people, so compare each rate with its own placebo group, not with another medicine.
Word for word
What each label says about headaches
Sentences from each label's warnings and side effect sections. Only cross-references are removed.
Ozempic, Rybelsus and Ozempic tablets, Saxenda: listed only among reports after approval, which come with no rate because nobody knows how many people took the medicine. Wegovy, Zepbound, Mounjaro, Foundayo, Trulicity, Victoza: no finding on this in the sections read here.
Not from trials
Reports to FDA about headaches
Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.
| Medicine | Reports naming | All reports on it |
|---|---|---|
| Ozempic | Headache: 2,937 | 70,863 |
| Byetta | Headache: 2,091 | 52,087 |
| Mounjaro | Headache: 2,090 | 97,440 |
| Zepbound | Headache: 1,828 | 80,835 |
| Victoza | Headache: 1,709 | 41,462 |
| Trulicity | Headache: 1,704 | 87,279 |
| Wegovy | Headache: 921 | 25,993 |
| Rybelsus and Ozempic tablets | Headache: 326 | 7,758 |
| Saxenda | Headache: 323 | 7,270 |
| Foundayo | Headache: 187 | 3,050 |
Counted through openFDA from FDA's Adverse Event Reporting System, refreshed weekly. One report can name several terms.
Updated automatically
Latest FDA label updates
- FDA labelFDA label updated: Zepbound (Eli Lilly and Company), effective 2026-08-28
- FDA labelFDA label updated: Mounjaro (Eli Lilly and Company), effective 2026-08-27
- FDA labelFDA label updated: Foundayo (Eli Lilly and Company), effective 2026-07-29
- FDA labelFDA label updated: Liraglutide (Meitheal Pharmaceuticals Inc.), effective 2026-07-27
- FDA labelFDA label updated: Liraglutide (NorthStar Rx LLC), effective 2026-06-24
Written from each source's own record as it changes. Every change on GLPcompare
Questions
Headache on a GLP-1: common questions
Which GLP-1 causes the most headaches?
No trial here ranks them. By the rates each label prints, Wegovy 2.4 mg is highest at 14% (placebo 10%) and Foundayo 17.2 mg lowest at 9% (placebo 7%). These come from separate trials with different people and doses, so compare each to its own placebo group.
Does Wegovy cause headaches?
In its FDA label, 14% of people taking Wegovy 2.4 mg reported headaches, against 10% on placebo.
Does Saxenda cause headaches?
In its FDA label, 13.6% of people taking Saxenda 3 mg reported headaches, against 12.6% on placebo.
Does Victoza cause headaches?
In its FDA label, 10% of people taking Victoza 1.8 mg reported headaches, against 7% on placebo.
Does Foundayo cause headaches?
In its FDA label, 9% of people taking Foundayo 17.2 mg reported headaches, against 7% on placebo.
Other side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Stomach pain
- Indigestion
- Acid reflux
- Burping
- Gas
- Bloating
- Fatigue
- Dizziness
- Hair loss
- Injection site reactions
- Skin sensitivity and tingling
- Taste changes
- Muscle loss
- Pancreatitis
- Gallbladder problems
- Low blood sugar
- Kidney problems
- Gastroparesis and severe stomach problems
- Allergic reactions
- Thyroid cancer
- Eye problems
- Fast heart rate
- Aspiration under anesthesia
- Depression and suicidal thoughts
- Birth control
- Drug interactions
- Metformin
- Pregnancy
- Breastfeeding
Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.